Teva Says FTC Can't Draw It Into Pay-For-Delay Case

Law360, New York (January 8, 2014, 7:16 PM EST) -- Generic drug giant Teva Pharmaceutical Industries Ltd. on Wednesday urged a Pennsylvania federal judge to deny a bid from the Federal Trade Commission to add the company to its antitrust pay-for-delay suit against Provigil maker Cephalon Inc., arguing its acquisition of Cephalon is irrelevant to the case.

In an opposition to the FTC's motion to add Teva to its suit, the company told the court that the government was improperly attempting to ensure it could impose relief against Teva and its business operations if its case against...
To view the full article, register now.